CY1115629T1 - Χρηση ενωσεων πεπτιδιου τρο και φαρμακευτικων συνθεσεων στην θεραπεια της αναιμιας - Google Patents

Χρηση ενωσεων πεπτιδιου τρο και φαρμακευτικων συνθεσεων στην θεραπεια της αναιμιας

Info

Publication number
CY1115629T1
CY1115629T1 CY20141100815T CY141100815T CY1115629T1 CY 1115629 T1 CY1115629 T1 CY 1115629T1 CY 20141100815 T CY20141100815 T CY 20141100815T CY 141100815 T CY141100815 T CY 141100815T CY 1115629 T1 CY1115629 T1 CY 1115629T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
trop
peptide compounds
anemia therapy
peptide compound
Prior art date
Application number
CY20141100815T
Other languages
English (en)
Inventor
Edward J Yurkow
Brian R Macdonald
Jeffery K Weis
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of CY1115629T1 publication Critical patent/CY1115629T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αποκαλύπτεται μία μέθοδος αγωγής της αναιμίας. Η μέθοδος περιλαμβάνει την χορήγηση μίας ένωσης πεπτιδίου ΤΡΟ σε ένα υποκείμενο. Αποκαλύπτονται επίσης φαρμακευτικές συνθέσεις που περιλαμβάνουν μία ένωση πεπτιδίου ΤΡΟ και έναν φαρμακευτικώς αποδεκτό φορέα καθώς και διαγνωστικές μέθοδοι που περιλαμβάνουν μία επισημασμένη ένωση πεπτιδίου ΤΡΟ.
CY20141100815T 2006-02-14 2014-10-08 Χρηση ενωσεων πεπτιδιου τρο και φαρμακευτικων συνθεσεων στην θεραπεια της αναιμιας CY1115629T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2006/005322 WO2007094781A1 (en) 2006-02-14 2006-02-14 Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia
EP06735131.2A EP1984014B1 (en) 2006-02-14 2006-02-14 Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia

Publications (1)

Publication Number Publication Date
CY1115629T1 true CY1115629T1 (el) 2017-01-04

Family

ID=37904365

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100815T CY1115629T1 (el) 2006-02-14 2014-10-08 Χρηση ενωσεων πεπτιδιου τρο και φαρμακευτικων συνθεσεων στην θεραπεια της αναιμιας

Country Status (19)

Country Link
EP (1) EP1984014B1 (el)
JP (1) JP2009526841A (el)
CN (1) CN101374540B (el)
AU (1) AU2006338308B2 (el)
BR (1) BRPI0621347B8 (el)
CA (1) CA2642389C (el)
CY (1) CY1115629T1 (el)
DK (1) DK1984014T3 (el)
EA (1) EA015562B1 (el)
ES (1) ES2516649T3 (el)
HK (2) HK1125055A1 (el)
IL (1) IL193268A (el)
NI (1) NI200800216A (el)
NO (1) NO341872B1 (el)
NZ (1) NZ570124A (el)
PL (1) PL1984014T3 (el)
PT (1) PT1984014E (el)
SI (1) SI1984014T1 (el)
WO (1) WO2007094781A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009256465B2 (en) * 2008-06-03 2015-05-14 Janssen Pharmaceutica Nv TPO mimetic peptide for preventing hematological disorder associated with cancer treatment
JP6150374B2 (ja) * 2012-11-15 2017-06-21 国立大学法人弘前大学 放射線被ばく治療剤及び放射線被ばく治療方法
US20200164039A1 (en) 2017-07-26 2020-05-28 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
JP2022519196A (ja) 2019-01-25 2022-03-22 ヤンセン ファーマシューティカ エヌ．ベー． 全身照射／化学曝露に対する応答において臓器および血管損傷、造血回復ならびに生存に対する保護を増強する方法
KR20210120037A (ko) 2019-01-25 2021-10-06 잔센파마슈티카엔.브이. 수포제 및 가성 가스의 독성 영향 경감 방법
AU2020211412A1 (en) 2019-01-25 2021-08-12 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
WO2023056444A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1843595A (en) * 1994-02-14 1995-08-29 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
MXPA05003057A (es) * 2002-09-18 2006-04-18 Johnson & Johnson Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
SG131110A1 (en) * 2003-08-28 2007-04-26 Ortho Mcneil Pharm Inc Peptides and compounds that bind to thrombopoietin receptors

Also Published As

Publication number Publication date
NZ570124A (en) 2011-05-27
NI200800216A (es) 2012-01-24
HK1129571A1 (en) 2009-12-04
EA200870261A1 (ru) 2009-02-27
WO2007094781A1 (en) 2007-08-23
CN101374540B (zh) 2013-03-06
NO341872B1 (no) 2018-02-12
IL193268A (en) 2015-02-26
EA015562B1 (ru) 2011-08-30
HK1125055A1 (en) 2009-07-31
EP1984014B1 (en) 2014-08-06
EP1984014A1 (en) 2008-10-29
PL1984014T3 (pl) 2015-02-27
CN101374540A (zh) 2009-02-25
AU2006338308A1 (en) 2007-08-23
CA2642389C (en) 2014-05-06
ES2516649T3 (es) 2014-10-31
NO20083928L (no) 2008-09-15
BRPI0621347B8 (pt) 2021-05-25
PT1984014E (pt) 2014-11-13
DK1984014T3 (da) 2014-09-15
SI1984014T1 (sl) 2014-12-31
CA2642389A1 (en) 2007-08-23
BRPI0621347A2 (pt) 2011-12-06
AU2006338308B2 (en) 2012-11-01
IL193268A0 (en) 2009-02-11
JP2009526841A (ja) 2009-07-23
BRPI0621347B1 (pt) 2018-05-08

Similar Documents

Publication Publication Date Title
CY1115629T1 (el) Χρηση ενωσεων πεπτιδιου τρο και φαρμακευτικων συνθεσεων στην θεραπεια της αναιμιας
CY1124166T1 (el) Συζευγματα αντισωματος φαρμακου (adc) τα οποια δεσμευονται σε 191p4d12 πρωτεϊνες
NO20065227L (no) Menoklonale antistoff mot hepatocytt vekstfaktor
CY1111721T1 (el) Ακυλαμινοπυραζολια ως αναστολεις fgfr
CY1106283T1 (el) Κινολινυλ-πυρρολοπυραζολες
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
EA201490254A1 (ru) Комбинированное лечение гепатита с
CY1109732T1 (el) Χρησις παραγωγων βενζο-συνενωμενου ετεροκυκλο σουλφαμιδιου δια την θεραπειαν πονου
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
ATE432279T1 (de) Tricyclische delta-opioid-modulatoren
TNSN07419A1 (en) Methods for treating drug resistant cancer
CY1117261T1 (el) [4-(5-αμινομεθυλο-2-φθορο-φαινυλο)-πιπεριδιν-1-υλο]-[7-φθορο-1-(2-μεθοξυ-αιθυλο)-4τριφθορο μεθοξυ-1η-ινδολ-3-υλο]-μεθανονη ως αναστολεας τρυπτασης maστοκυτταρων
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
EA200700403A1 (ru) ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ
AR059945A1 (es) Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion taci-ig
UY29069A1 (es) Uso de compuestos tpo miméticos y composiciones farmacéuticas para el tratamiento de la anemia
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
EA200702136A1 (ru) Композиции станнсопорфина и их применение
AR048068A1 (es) Piperazinas derivadas de urea para el tratamiento de endometriosis
ATE540920T1 (de) Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie
ATE505483T1 (de) Derivate des biologisch aktiven peptids vapeehptllteaplnpk
CY1113495T1 (el) Χρηση μιας συνθεσης που περιλαμβανει μια ενωση υδροκινονης, ακετονιδιου φθοριοκινολονης και τρετινοϊνης, που προοριζεται για τη θεραπεια δερματικων σημαδιων φωτογηρανσης
MY151422A (en) Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia
MY151332A (en) Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia
ATE454144T1 (de) Behandlung von malignen neoplasien